Regeneron Pharmaceuticals, Inc.’s move to publicly broadcast its decision to “offer” Democratic Presidential Candidate Joe Biden’s team access to its experimental cocktail of two monoclonal antibodies for COVID-19 may run afoul of US Food and Drug Administration regulations surrounding promotion of unapproved products.
Any chance of the agency taking enforcement action seems remote, but the incident underscores the legal and ethical minefields that...






